9 known cases. View patent page →
Related patent-infringement action asserting the '517, '230, '740, '569, '357 and '219 patents; consolidated with the 2010 action by order dated November 9, 2012. The narrative could not confirm that the '554 patent was separately asserted in this 2012 action.
Listed on the patent record; caption and outcome unverified.
16-count complaint with the '740 patent among patents-in-suit; motion for judgment on the pleadings on REMS patents denied without prejudice Dec 14, 2018. Later settled March 30, 2019, with Lotus/Alvogen licensed to sell a limited-volume generic after March 2022.
Celgene action against Apotex; settled around 2021 amid allegations of a reverse-payment/profit-share agreement.
Antitrust follow-on litigation where purchasers/insurers allege Celgene used the '740 and related method-of-treatment patents, serial sham suits, and reverse-payment settlements to delay generic lenalidomide. The court dismissed the insurer and MSP operative complaints on June 6, 2024, with later amended complaints filed.
Celgene action against Cipla; settled Dec 11, 2020, with a volume-limited license and entry in Sept 2022.
Celgene action against Hetero Labs Limited et al.; settled/licensed under later-filer volume allocation.
ANDA action asserting '740 and '800, '498, '569, '217, '120, '622, '095, '717, '621. Answer/counterclaim June 22, 2021; joint discovery plan Aug 4, 2021. Later closed (settled/licensed).
IPR petition challenging U.S. Patent 7,189,740; not instituted/institution denied Feb 11, 2019; notice of refund July 2019.